SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-24-031923
Filing Date
2024-07-16
Accepted
2024-07-16 07:36:46
Documents
16
Period of Report
2024-07-15
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K avtx-20240715.htm   iXBRL 8-K 36886
2 EX-10.1 exhibit101_mdxcmo.htm EX-10.1 86476
3 EX-99.1 ex-991cmoappointment.htm EX-99.1 18909
7 GRAPHIC avalologo.jpg GRAPHIC 8535
  Complete submission text file 0001628280-24-031923.txt   303639

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT avtx-20240715.xsd EX-101.SCH 1969
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT avtx-20240715_lab.xml EX-101.LAB 21026
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT avtx-20240715_pre.xml EX-101.PRE 12041
18 EXTRACTED XBRL INSTANCE DOCUMENT avtx-20240715_htm.xml XML 2625
Mailing Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850
Business Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850 410-522-8707
Avalo Therapeutics, Inc. (Filer) CIK: 0001534120 (see all company filings)

IRS No.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37590 | Film No.: 241118591
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)